Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

No abstract is available for this paper.

• Publication year

  1993

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1993-12-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.90.24.11825PMID 7903454PMCID PMC48077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine.

  1993cited by this paper
• Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

  1992cited by this paper
• Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population

  1992cited by this paper
• Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S‐mephenytoin

  1992cited by this paper
• Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

  1991cited by this paper
• Interethnic variation of drug metabolism.

  1991cited by this paper
• Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

  1990cited by this paper
• DNA amplification is rare in normal human cells.

  1990cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• Molecular cloning : a laboratory manual. Cold Spring Harbor, NY

  1989cited by this paper
• De novo amplification within a "silent" human cholinesterase gene in a family subjected to prolonged exposure to organophosphorous insecticides.

  1989cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

  1988cited by this paper
• The molecular biology of cytochrome P450s.

  1988cited by this paper
• Human cancer and cellular oncogenes.

  1987cited by this paper
• DNA amplification in drug resistant cells and in tumours.

  1986cited by this paper
• c-Ha-ras-1 proto-oncogene amplification and overexpression during the limited replicative life span of normal human fibroblasts.

  1985cited by this paper
• In vivo somatic mutations in human lymphocytes frequently result from major gene alterations

  1985cited by this paper
• Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

  1985cited by this paper
• Gene amplification in cultured animal cells.

  1984cited by this paper
• Gene amplification.

  1984cited by this paper
• Gene amplification causes overproduction of the first three enzymes of UMP synthesis in N-(phosphonacetyl)-L-aspartate-resistant hamster cells.

  1979cited by this paper
• Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured murine cells.

  1978cited by this paper

• The Evolving Landscape of Pharmacogenomics: Current Achievements and Future Directions

  2026cites this paper
• Pharmacogenomic Testing in the Clinical Laboratory: Historical Progress and Future Opportunities

  2025cites this paper
• Dietary‐Driven Gene Expansion

  2025cites this paper
• Advancing paroxetine treatment in depression: predicting remission and plasma concentration, and validating and updating therapeutic reference ranges

  2025cites this paper
• The 75-Year Anniversary of the Department of Physiology and Pharmacology at Karolinska Institutet—Examples of Recent Accomplishments and Future Perspectives

  2024cites this paper
• Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis

  2024cites this paper
• Molecular mechanisms underlying single nucleotide polymorphism-induced reactivity decrease in CYP2D6

  2024cites this paper
• Reflections on the Lack of Consideration of Ethnic Ancestry to Stratify Clozapine Dosing

  2023cites this paper
• Statin-Induced Myopathy

  2023cites this paper
• Statin associated muscle symptoms (SAMS): strategies for prevention, assessment and management

  2023cites this paper
• PharmVar Tutorial on CYP2D6 Structural Variation Testing and Recommendations on Reporting

  2023cites this paper
• A paradigm shift in pharmacogenomics: From candidate polymorphisms to comprehensive sequencing

  2022cites this paper
• PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus

  2022cites this paper
• PacBio long-read amplicon sequencing enables scalable high-resolution population allele typing of the complex CYP2D6 locus

  2022cites this paper
• Genomic diversity and post-admixture adaptation in the Uyghurs

  2021cites this paper
• Drug Metabolism: Cytochrome P450

  2021cites this paper
• Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction

  2021influential citation
• Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy

  2021cites this paper
• Integrated Role of Nanotechnology and Pharmacogenetics in Diagnosis and Treatment of Diseases

  2021cites this paper
• Segmental duplications and their variation in a complete human genome

  2021cites this paper
• Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics

  2021cites this paper
• Recommendations for Clinical CYP2D6 Genotyping Allele Selection: A Joint Consensus Recommendation of the Association for Molecular Pathology, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, and European Society for Pharmacogenomics a

  2021cites this paper
• A systematic comparison of pharmacogene star allele calling bioinformatics algorithms: a focus on CYP2D6 genotyping

  2020cites this paper
• Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics

  2020cites this paper
• Pharmacogenetic studies of thiopurine methyltransferase genotype-phenotype concordance and effect of methotrexate on thiopurine metabolism

  2020cites this paper
• Pharmacogenomics and Psychopharmacology

  2020cites this paper
• Is there a place for genetics in the management of PONV?

  2020cites this paper
• Self-Report for Measuring and Predicting Medication Adherence: Experts’ Experience in Predicting Adherence in Stable Psychiatric Outpatients and in Pharmacokinetics

  2020cites this paper
• How Can Drug Metabolism and Transporter Genetics Inform Psychotropic Prescribing?

  2020cites this paper
• PPA_A_242693 1823..1842

  2020cites this paper
• ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone.

  2020cites this paper
• A history of the roles of cytochrome P450 enzymes in the toxicity of drugs

  2020cites this paper
• Principles of Pharmacogenomics

  2019cites this paper
• Pharmacogenomics

  2019cites this paper
• Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing

  2019cites this paper
• Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences

  2019cites this paper
• Multiplex allele-specific PCR to determine genotypes at statin metabolizing SNP loci- rs1135840 and rs776746

  2019cites this paper
• Effect of FDA Warning on Codeine and Alternate Opioid Prescribing After Pediatric Dental Procedures in Ohio.

  2019cites this paper
• Pharmacogenomics in Hypertension: Where We Stand Today

  2019cites this paper
• Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine

  2018cites this paper
• Clinical pharmacology in Stockholm 50 years—report from the jubilee symposium

  2018cites this paper
• Genetic Polymorphisms and In Silico Mutagenesis Analyses of CYP2C9, CYP2D6, and CYPOR Genes in the Pakistani Population

  2018cites this paper
• CYP2D6 genotype can help to predict effectiveness and safety during opioid treatment for chronic low back pain: results from a retrospective study in an Italian cohort

  2018cites this paper
• Effects of CYP2D6*4 Polymorphism in the Developmet of Ploygenetic Diseases in Chechen Poplulation

  2018cites this paper
• Accurately genotyping CYP2D6: not for the faint of heart.

  2018cites this paper
• Falk Symposium 156: Genetics in Liver Disease Pharmacogenetics

  2018cites this paper
• Predicting CYP2D6 phenotype from resting brain perfusion images by gradient boosting.

  2017cites this paper
• Ninety-nine independent genetic loci influencing general cognitive function include genes associated with brain health and structure (N = 280,360)

  2017cites this paper
• Pharmacogenetics: a general review on progress to date.

  2017cites this paper
• Computational Analysis of Physicochemical Factors Driving CYP2D6 Ligand Interaction.

  2017cites this paper
• CYP2D6 polymorphisms are associated with effects of risperidone on neurocognitive performance in schizophrenia.

  2017cites this paper
• Cytochrome P450 2D6 and Parkinson’s Disease: Polymorphism, Metabolic Role, Risk and Protection

  2017cites this paper
• Lessons from Cuba for Global Precision Medicine: CYP2D6 Genotype Is Not a Robust Predictor of CYP2D6 Ultrarapid Metabolism

  2017cites this paper
• Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19

  2017cites this paper
• A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events

  2017cites this paper
• Digital PCR for determination of cytochrome P450 2D6 and sulfotransferase 1A1 gene copy number variations.

  2017cites this paper
• Pharmacogenetic Testing

  2017cites this paper
• Investigation of CYP2D6 Gene Polymorphisms in Turkish Population.

  2016cites this paper
• Comparative Pharmacology and Guide to the Use of the Serotonin 5-HT3 Receptor Antagonists for Postoperative Nausea and Vomiting

  2016cites this paper
• Presystemic and First‐Pass Metabolism

  2016cites this paper
• Functional characterization of CYP2D6 novel allelic variants identified in the Chinese Han population.

  2016cites this paper
• Molecular mechanisms of statin intolerance

  2016cites this paper
• Analysis of Structural Chromosome Variants by Next Generation Sequencing Methods

  2016cites this paper
• Pharmacogenetics of CYP2D6 and tamoxifen therapy: Light at the end of the tunnel?

  2016cites this paper
• Zinc Fingers and Homeoboxes 2 (Zhx2) Regulates Sexually Dimorphic Cyp Gene Expression in the Adult Mouse Liver.

  2016cites this paper
• Simultaneous Determination of Cytochrome P450 Oxidation Capacity in Humans: A Review on the Phenotyping Cocktail Approach.

  2016cites this paper
• Pharmacogenetics and Personalized Medicine in Pain Management.

  2016cites this paper
• The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting

  2016cites this paper
• The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients

  2016cites this paper
• A Physiologic Approach to the Pharmacogenomics of Hypertension.

  2016cites this paper
• Mass Spectrometry in Precision Medicine: Phenotypic Measurements Alongside Pharmacogenomics.

  2016cites this paper
• Role of pharmacogenetics for the improvement of cancer treatment

  2016cites this paper
• CYP2D6 allele distribution in Macedonians, Albanians and Romanies in the Republic of Macedonia

  2015cites this paper
• Addressing phenoconversion: the Achilles' heel of personalized medicine

  2015cites this paper
• The impact of genetics, environmental, and geographical factors on inter-individual and inter-ethnic differences in CYP2C9-catalysed drug metabolism

  2015cites this paper
• Genetic Variations in the Macaca fascicularis Genome Related to Biomedical Research

  2015cites this paper
• ZHX2 REGULATION OF LIPID METABOLISM AND THE BALANCE BETWEEN CARDIOVASCULAR AND HEPATIC HEALTH

  2015cites this paper
• The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding.

  2015cites this paper
• Codein: Neue Anwendungsbeschränkungen bei Kindern und Jugendlichen

  2015cites this paper
• Pharmacogenetics: an Emerging Therapeutic Option for Bangladesh

  2015cites this paper
• Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland

  2015cites this paper
• CLINICALLY RELEVANT OF CYTOCHROME P 450 FAMILY ENZYMES FOR DRUG-DRUG INTERACTION IN ANTICANCER THERAPY

  2015cites this paper
• The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding

  2015cites this paper
• Farmacogenética del "CYP2D6" en la población argentina general y judía Ashkenazi

  2015cites this paper
• Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia

  2014cites this paper
• Implementation Consortium Guidelines for Cytochrome P 450 2 D 6 Genotype and Codeine Therapy : 2014 Update

  2014cites this paper
• Drug Response Heterogeneity and the Genetic Variability of Cytochrome P450–Metabolizing Enzymes

  2014cites this paper
• CYP2D6: interethnic variability

  2014cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update

  2014cites this paper
• Pharmacogenetics of chronic pain management.

  2014cites this paper
• Influence of Cytochrome P450, Family 2, Subfamily D, Polypeptide 6 (CYP2D6) polymorphisms on pain sensitivity and clinical response to weak opioid analgesics.

  2014cites this paper
• Genetic variability ofCYP2D6:basic and clinical aspects

  2014cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update

  2014cites this paper
• Análisis, validación y estudio poblacional de las inversiones entre dos genomas humanos

  2014cites this paper
• Chapter 4 – Drug Metabolism and Pharmacogenetics

  2013cites this paper
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants

  2013cites this paper
• In vitro hepatic metabolism of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47) and 2,2',4,4',5-pentabromodiphenyl ether (BDE-99)

  2013cites this paper
• Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes

  2013cites this paper
• Impacts of variation in the human genome on gene regulation.

  2013cites this paper
• Cytochrome P450-Mediated Changes in Oxycodone Pharmacokinetics/Pharmacodynamics and Their Clinical Implications

  2013cites this paper